title: Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
abstract: BACKGROUND
  Non-compliance with medication often has long-term detrimental effects in patients with schizophrenia. However, when patients are compliant, it is not certain whether they experience short-term improved quality of life. By simultaneously reducing symptoms and increasing side-effects, compliance with antipsychotics may have opposing effects on a patient's perceived quality of life.
  
  
  OBJECTIVE
  This study aimed to identify any clinical-empirical evidence for two pathways between compliance and quality of life.
  
  
  METHODS
  To evaluate various pathways between compliance (Service Engagement Scale plus a one-item rating), psychotic symptoms (Positive and Negative Syndromes Scale), adverse medication effects (Subjective Wellbeing under Neuroleptics scale), and quality of life (EQ-5D), we used Structural Equation Modeling on cross-sectional data of 114 patients with a psychotic disorder.
  
  
  RESULTS
  Compliance was not directly related to quality of life (r=0.004). The best-fitting model (chi(2)=1.08; df=1) indicated that high compliance was associated with fewer psychotic symptoms (beta=-0.23) and more adverse medication effects (beta=0.22). Symptoms (beta=-0.17) and adverse medication effects (beta=-0.48) were both related to lower quality of life.
  
  
  CONCLUSIONS
  Our results suggest that compliance with antipsychotics has two opposing pathways towards quality of life, albeit indirect ones. While compliance was associated with less severe psychotic symptoms, and was thus related to higher quality of life, it was also associated with more adverse medication effects, and was thus related to lower quality of life. However, due to our study design, we cannot draw firm conclusions on causality. Two possible clinical implications of the results for compliance and interventions are discussed.
authors.affiliation: Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. tonnie@backwash.org
authors.forename: A B P
authors.initials: AB
authors.lastname: Staring
authors.forename: C L
authors.initials: CL
authors.lastname: Mulder
authors.forename: H J
authors.initials: HJ
authors.lastname: Duivenvoorden
authors.forename: L
authors.initials: L
authors.lastname: De Haan
authors.forename: M
authors.initials: M
authors.lastname: Van der Gaag
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D011569:Psychiatric Status Rating Scales; D011599:Psychopathology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents